Kintor Pharmaceutical Limited



简体

繁体

搜索

PREV 

NEXT 

About Us

Kintor Pharmaceuticals focuses on developing drugs for androgen-receptor-related diseases with significant unmet medical needs，

including prostate cancer, alopecia, acne, liver cancer, breast cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Small-molecule drugs

Kintor Pharmaceuticals product pipeline initially focused on androgen receptor (AR) antagonists. Our expanded pipeline now includes mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents, and cMyc inhibitors.

Innovative biologics

Kintor Pharmaceuticals' first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers.

Combination therapies

To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharmaceuticals is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a multidisciplinary team of drug developers.

Manufacturing Base

Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing base in Suzhou.

Commercial Operation

In anticipation of the commercial launch of our products, Kintor Pharmaceuticals is building an independent commercialization team. [entity?]

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2023-03-21

Kintor Pharma’s KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential and representative of all dermatologic associations, dermatologists from around the world shared the latest research advances in the field of dermatology. Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939)’s self-developed and potential first-in-class topical drug candidates pyrilutamide (KX-826) and GT20029 have attracted a lot of attention at the meeting, demonstrating the company's innovative capabilities and the therapeutic potential of its androgenetic alopecia (AGA) and acne pipelines.

2023-03-16

Kintor Pharma Announces Preclinical Data of GT1708F at AACR 2023

Suzhou, March 16, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the latest preclinical data from the company’s hedgehog inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) has been selected for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting, and the abstract is available on AACR’s official website.

2023-02-10

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

Suzhou, February 10, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. The data showed GT20029 was safe, well tolerated and had good pharmacokinetic characteristics in healthy subjects as well as subjects with androgenetic alopecia (AGA) or acne. GT20029 is the first topical PROTAC compound in the world which has completed Phase I clinical trial in both China and the U.S..